Table 3 Association between clinical characteristics and post-progression survival among 288 patients with advanced stage lung adenocarcinoma and available data of CEAIn and CEAPd, stratified by EGFR mutation status.

From: Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression

Predictor

EGFR wild-type (n = 94)

EGFR mutant (n = 194)

aHR (95% CI)

P value

aHR (95% CI)

P value

Age ≥ 65 years

1.82 (1.04–3.19)

0.036

0.82 (0.57–1.18)

0.277

Male sex

1.73 (0.95–3.15)

0.072

1.32 (0.83–2.11)

0.241

Stage IV

2.39 (1.19–4.81)

0.015

3.43 (1.63–7.22)

0.001*

Ever smoking

1.17 (0.63–2.16)

0.624

0.68 (0.41–1.14)

0.142

CEAIn

   <5 ng/mL

Reference

 

Reference

 

   5–100 ng/mL

1.50 (0.70–3.23)

0.300

0.61 (0.36–1.01)

0.057

   >100 ng/mL

1.13 (0.39–3.25)

0.823

0.43 (0.22–0.85)

0.014

CEAPd

   <5 ng/mL

Reference

 

Reference

 

   5–100 ng/mL

1.28 (0.59–2.79)

0.531

2.55 (1.48–4.42)

0.001*

   >100 ng/mL

1.94 (0.75–5.03)

0.175

4.39 (2.22–8.70)

<0.001*

  1. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; CEAIn, serum carcinoembryonic antigen level at initial diagnosis; CEAPd, serum carcinoembryonic antigen level at disease progression;
  2. *Statistically significant after a Bonferroni adjustment at P < 0.0071.
Back to article page